[go: up one dir, main page]

ME02877B - Terapeutsko sredstvo za anksiozne poremećaje - Google Patents

Terapeutsko sredstvo za anksiozne poremećaje

Info

Publication number
ME02877B
ME02877B MEP-2017-233A MEP23317A ME02877B ME 02877 B ME02877 B ME 02877B ME P23317 A MEP23317 A ME P23317A ME 02877 B ME02877 B ME 02877B
Authority
ME
Montenegro
Prior art keywords
disorder
anxiety disorder
prophylaxis
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MEP-2017-233A
Other languages
German (de)
English (en)
French (fr)
Inventor
Junya Kase
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of ME02877B publication Critical patent/ME02877B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (4)

1. Derivat tiazola predstavljen formulom (IC) ili njegova farmaceutski prihvatljiva so, naznačen time što je za upotrebu u tretmanu i/ili profilaksi anksioznog poremećaja.
2. Derivat tiazola ili njegova farmaceutski prihvatljiva so u skladu sa patentnim zahtevom 1, naznačen time što je za upotrebu u tretmanu i/ili profilaksi anksioznog poremećaja izabranog od paničnog poremećaja, agorafobije, opsesivno kompulzivnog poremećaja, socijalne fobije, posttraumatskog stresnog poremećaja, specifične fobije, generalizovanog anksioznog poremećaja.
3. Upotreba derivata tiazola opisanog u patentnom zahtevu 1 ili njegove farmaceutski prihvatljive soli za produkciju sredstva za tretman i/ili profilaksu anksioznog poremećaja.
4. Upotreba u skladu sa patentnim zahtevom 3, naznačena time što je anksiozni poremećaj panični poremećaj, agorafobija, opsesivno kompulzivni poremećaj, socijalna fobija, posttraumatski stresni poremećaj, specifična fobija, generalizovani anksiozni poremećaj.
MEP-2017-233A 2009-09-02 2010-09-02 Terapeutsko sredstvo za anksiozne poremećaje ME02877B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (ja) 2009-09-02 2010-09-02 不安障害治療剤
EP10813754.8A EP2474544B1 (en) 2009-09-02 2010-09-02 Therapeutic agent for anxiety disorders

Publications (1)

Publication Number Publication Date
ME02877B true ME02877B (me) 2018-04-20

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-233A ME02877B (me) 2009-09-02 2010-09-02 Terapeutsko sredstvo za anksiozne poremećaje

Country Status (32)

Country Link
US (1) US20120172362A1 (me)
EP (1) EP2474544B1 (me)
JP (1) JP5663485B2 (me)
KR (2) KR20120047311A (me)
CN (1) CN102482271A (me)
AU (1) AU2010290424C1 (me)
BR (1) BR112012004850A2 (me)
CA (1) CA2772922C (me)
CL (1) CL2012000533A1 (me)
CY (1) CY1119483T1 (me)
DK (1) DK2474544T3 (me)
DO (1) DOP2012000056A (me)
EA (1) EA023728B1 (me)
ES (1) ES2643840T3 (me)
GE (1) GEP20156225B (me)
HR (1) HRP20171418T1 (me)
HU (1) HUE036543T2 (me)
IL (1) IL218320A (me)
LT (1) LT2474544T (me)
MA (1) MA33619B1 (me)
ME (1) ME02877B (me)
MX (1) MX2012002529A (me)
NZ (1) NZ598754A (me)
PL (1) PL2474544T3 (me)
PT (1) PT2474544T (me)
RS (1) RS56401B1 (me)
SI (1) SI2474544T1 (me)
SM (1) SMT201700465T1 (me)
TN (1) TN2012000093A1 (me)
UA (1) UA113383C2 (me)
WO (1) WO2011027806A1 (me)
ZA (1) ZA201202347B (me)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3002283T (lt) * 2003-12-26 2017-09-11 Kyowa Hakko Kirin Co., Ltd. Tiazolo dariniai
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331843T2 (de) 1992-07-08 2002-09-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine-Derivate als Antidepressiva
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
EP1631294B1 (en) 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
LT3002283T (lt) * 2003-12-26 2017-09-11 Kyowa Hakko Kirin Co., Ltd. Tiazolo dariniai
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
ES2643340T3 (es) 2005-08-02 2017-11-22 Kyowa Hakko Kirin Co., Ltd. Agentes para tratar y/o prevenir trastornos del sueño
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
IL218320A0 (en) 2012-04-30
ZA201202347B (en) 2015-11-25
MX2012002529A (es) 2012-04-11
SMT201700465T1 (it) 2017-11-15
NZ598754A (en) 2014-08-29
SI2474544T1 (sl) 2017-11-30
LT2474544T (lt) 2017-10-25
AU2010290424C1 (en) 2016-02-18
US20120172362A1 (en) 2012-07-05
CL2012000533A1 (es) 2012-09-14
AU2010290424B2 (en) 2015-11-05
IL218320A (en) 2016-06-30
MA33619B1 (fr) 2012-09-01
EP2474544B1 (en) 2017-07-12
AU2010290424A1 (en) 2012-04-19
ES2643840T3 (es) 2017-11-24
HUE036543T2 (hu) 2018-07-30
PL2474544T3 (pl) 2017-12-29
CN102482271A (zh) 2012-05-30
KR20170044768A (ko) 2017-04-25
CA2772922C (en) 2017-11-21
KR20120047311A (ko) 2012-05-11
UA113383C2 (xx) 2017-01-25
JPWO2011027806A1 (ja) 2013-02-04
TN2012000093A1 (en) 2013-09-19
RS56401B1 (sr) 2018-01-31
CY1119483T1 (el) 2018-03-07
EP2474544A1 (en) 2012-07-11
EA201270360A1 (ru) 2012-09-28
HRP20171418T1 (hr) 2017-11-03
CA2772922A1 (en) 2011-10-03
EP2474544A4 (en) 2013-01-23
BR112012004850A2 (pt) 2020-06-23
DOP2012000056A (es) 2012-06-30
GEP20156225B (en) 2015-01-26
WO2011027806A1 (ja) 2011-03-10
EA023728B1 (ru) 2016-07-29
DK2474544T3 (en) 2017-10-02
PT2474544T (pt) 2017-10-03
JP5663485B2 (ja) 2015-02-04

Similar Documents

Publication Publication Date Title
UA109547C2 (uk) Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
BR112015009913A8 (pt) composições farmacêuticas para o tratamento de doenças mediadas por cftr
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
CO6680699A2 (es) Derivados de amina para el control de plagas
ME02877B (me) Terapeutsko sredstvo za anksiozne poremećaje
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
MX2011013706A (es) Derivados de tiazoliliperidina como fungicidas.
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
ATE454380T1 (de) Organische verbindungen zur behandlung entzündlicher oder allergischer leiden
DK2105164T3 (da) Nye P2X7R-antagonister og deres anvendelse
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
WO2011009533A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10) -dien-11-ethinylphenyl-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
WO2011009532A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.